South Korea’s IP-backed lending market growth exceeds targets
Although heavy reliance on government-backed initiatives creates uncertain future for IP holders
Although heavy reliance on government-backed initiatives creates uncertain future for IP holders
The Korean chemicals giant will do anything to combat “harsh competition” and IP is one of the “crucial” tools for securing success, contends IP head Kyung-Hwa Min
The global scientific and engineering consultancy has bought TechPats, a patent-focused technical expert firm, at a time when an uncertain economy and declining number of M&As has led some companies to issue layoff notices to IP staff
The agreement is the first granting non-exclusive and royalty free rights to sub-licensees of a covid therapeutic or vaccine
02 November 2021
In the wake of the firm’s latest $250 million investment, Sagard Healthcare Royalty Partners’ Ali Alagheband gives the inside track on life sciences IP-backed revenue sales
01 November 2021
Royalties grow on the back of new deals and renewals; company also shares new details on legal fight with Oppo, which does not appear to have significantly dimmed income outlook
29 October 2021
New Crinetics spin-off is more evidence of the growing influence of models designed to monetise non-core life sciences assets
22 October 2021
Diagnostic innovation buyouts drive resurgence of med-tech deal-making
19 October 2021
Continued impact of Samsung deal pushes Swedish company’s royalty take near $300 million – but executives warn upcoming re-negotiations could produce temporary disruption again
19 October 2021
Merck has struck the biggest life sciences M&A deal of 2021 so far. Here are the four key IP-related takeaways.
07 October 2021
US federal court victory sets up the $13.4 billion drug for exclusivity until 2028
05 October 2021
Assignment records show that despite parent company’s vast backing for startups, Softbank Corp and its affiliates have not often come into the possession of significant third-party portfolios
04 October 2021
The Long Read: Companies in the life sciences sector have increasing options when seeking outside investment in IP enforcement campaigns, writes Michael Gulliford. But unique legal considerations and risk factors call for careful structuring of deals
29 September 2021
Unlock unlimited access to all IAM content